UAE’s Globalpharma targets market for generic Ozempic

Globalpharma is preparing to manufacture generic versions of blockbuster weight-loss drugs like Ozempic and Mounjaro.

The Dubai Investments subsidiary is partnering internationally to develop peptide-based injectables using off-patent precursors, aligning with national goals to localise pharmaceutical production.

“The capability to produce, develop and analyse is what we are working on,” Dr. Basem Al-Barahmeh, the company’s General Manager, told Arabian Gulf Business Insights.

Globalpharma has more than doubled sales since 2019 and expects revenues to triple this year, with projections exceeding $150 million.

With two UAE plants producing 40 million medicine packs annually, Globalpharma is preparing for local production of complex injectables once regulatory approvals are secured.